Few positives seen for Valeant Pharmaceuticals International Inc ahead of March 15 conference call

Michael Pearson may still be considered by some as the best person to run Valeant going forward, but that doesn't mean the share price has room to run higher anytime soon.

Michael Pearson can always be looked at by a few because the best person to run Valeant Pharmaceuticals International Inc. moving forward, but that doesn’t mean the proportion price has room to operate higher anytime soon.

Investors and analysts expect Valeant will lower its 2016 revenue guidance when it holds a rescheduled business call on March 15.

However, the pharma giant still has a comparatively attractive portfolio which includes IBS drug Xifaxan, fungus treatment Jublia, consumer and phone lens assets, in addition to several older resilient brands.

As an effect, Mizuho analyst Irina Koffler thinks Valeant will be able to achieve single digit organic development in 2017.


About admin


Check Also


Twitter Inc’s user growth stalls as sales forecast falls short of estimates

Twitter Inc. said it didn’t add new users in the fourth quarter and forecast first-quarter ...


Manulife Financial Corp profit slides 62% as energy investments take a hit: ‘A disappointing year’

TORONTO – Energy exposure hit the conclusion of Manulife Financial Corp. in the fourth quarter, ...


Pension funds hope for better deal in de-risking marketplace

A pension risk exchange – an online marketplace that aims to create those defined benefit ...